Transcriptomic analysis reveals that Taz activates a range of molecules involved in antigen presentation, including human leukocyte antigen (HLA) molecules and transporter associated with antigen processing (TAP), suggesting that EZH2 inhibition may also enhance antigen presentation‐related processes, thereby boosting tumor immunogenicity (Figure S8A, Supporting Information). Here, EZH2 is linked to neoplasm.